Floatz logo

nkt5097 cdk2/cdk4 dual degrader

HR+ HER2- Breast Cancer

NiKang Therapeutics, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the HR+ HER2- Breast Cancer cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Faeth Therapeutics
Phase 1/2CCC
Canagliflozin
Faeth Therapeutics
Phase 1/2CC
Tak-228
Faeth Therapeutics
Phase 1/2CC
Serabelisib
Faeth Therapeutics
Phase 1/2CC
Letrozole
NiKang Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

nkt5097 cdk2/cdk4 dual degrader is also rated in:

hormone receptor-positive breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
CCNE1 Amplified Advanced Solid TumorsDormant
CC
Indicative ·
43 / 100
View asset →
triple-negative breast carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →